Insight Series

October 19, 2023 | 11:00 AM CT

In utero stem cell transplantation (IUTx) and in utero gene therapy (IUGT) offer the opportunity of treating, and ideally curing, a wide range of genetic disorders. Despite recent progress, there is an urgent need to explore novel cell and gene therapy tools for prenatal application and the ethical considerations surrounding this topic.  

Speakers

• Moderators: Afrooz Rashnonejad, PhD - Nationwide Children's Hospital, and William Peranteau, MD - Children's Hospital of Philadelphia

• Alan Flake, MD - Children's Hospital of Philadelphia
  Using insights from the past and lessons from the present to create the future of prenatal cell therapy

• Christopher Porada, PhD - Wake Forest Institute for Regenerative Medicine
  Harnessing the potential of in utero gene therapy

• Tippi MacKenzie, MD - University of California San Francisco
  Clinical trials on fetal cell therapy, briefly touching on regulatory aspect 

• Saskia Hendriks, MD, PhD - National Institutes of Health
  Ethical considerations for prenatal cell and gene therapies

Watch on demand

More ASGCT Insights

Register for more sessions during ASGCT Insights Week, Oct. 16-20. Members and registrants can watch on demand!

• Oct. 16: Best of ASGCT: Annual Meetings Recent Top Abstracts Revisited

• Oct. 17: Risk Assessment of Lentiviral and AAV Gene Therapy Vectors

• Oct. 18: Risk Assessment for Gene Editing Technologies and Outcomes

• Oct. 20: Friend or Foe? Interplay Between Innate Immune Responses and Non-viral Gene Delivery